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Endocardial lead–related tricuspid regurgitation (ELTR) is
an increasingly recognized complication of cardiac device
implantation that can result in right ventricular (RV)
dysfunction and right heart failure.1 Several mechanisms of
ELTR have been proposed, including lead impingement on
tricuspid valve (TV) leaﬂets; leaﬂet perforation; entangle-
ment within the valve apparatus; adherence to TV leaﬂets,
chordae, or papillary muscles; and altered RV activation or
geometry owing to RV pacing.1,2 Irrespective of the mech-
anism(s) involved, it has been postulated that the mechanical
and hemodynamic consequences of ELTR on the TV and RV
should manifest by 6 months post–device implantation,
delineating the time period during which compatible signs
and symptoms should most raise suspicion for this condition
and suggesting that early intervention may be important.1
Though both surgical and percutaneous treatment options
for ELTR have been reported, surgery has been advocated as
the default treatment by some, in part because of a perceived
high risk of procedural complications with percutaneous
options, including damage to the TV.3 However, case series
of patients undergoing TV surgery for isolated severe
tricuspid regurgitation (TR), including cases of ELTR, have
reported considerable operative morbidity and short-term
mortality as high as 19%.4–6 In contrast, major complications
occur in o0.8% of patients undergoing contemporary
percutaneous lead removal at experienced centers7 and in
as little as 0% of cases involving leads less than 1 year old.8
Nevertheless, the role of percutaneous interventions for
ELTR remains unclear, with 3 reports suggesting unpredict-
able improvements in TR and RV function with thisKEYWORDS Tricuspid regurgitation; Pacemaker; Lead extraction; Iatrogenic
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(http://creativecommons.org/licenses/by-nc-nd/4.0/).approach.9–11 We describe a patient with severe, sympto-
matic ELTR associated with RV dysfunction and tricuspid
annular dilatation that resolved between 10 and 12 months
after percutaneous ventricular lead extraction.Case report
An 84-year-old woman with paroxysmal atrial ﬁbrillation
(AF), hypertension, mild cognitive impairment, and remote
upper gastrointestinal bleed presented to hospital with
palpitations. She was noted to have prolonged postconver-
sion sinus pauses on telemetry with presyncope and therefore
underwent an uncomplicated dual-chamber permanent pace-
maker (PPM) implantation (Sensia; Medtronic, Minneapolis,
MN). A transthoracic echocardiogram (TTE) performed
prior to device implantation documented normal biventric-
ular size and systolic function, as well as mild mitral
regurgitation and mild TR.
Within several weeks she began to complain of “ﬂuid
retention,” requiring readmission to hospital approximately 6
months post–PPM implantation because of progressive
dyspnea, fatigue, marked peripheral edema, and gross
ascites. TTE showed new severe TR (Figure) and moderate
RV dysfunction, as well as mild left ventricular (LV)
dysfunction with an LV ejection fraction (LVEF) of 45%–
50% (see Supplementary Table 1 and Video, available
online, for details of all echocardiographic studies). Inter-
rogation of her PPM revealed sustained AF and minimal RV
pacing. A 3-dimensional echocardiogram (3DE) demon-
strated that the ventricular lead ran in the TV posteroseptal
commissure with evidence of resultant restriction predom-
inantly of septal leaﬂet excursion (Figure). Clinically, the
patient continued to deteriorate despite aggressive diuresis.
Following discussions with the patient and her family, it
was decided to percutaneously remove the RV lead. This was
performed using a lead locking device and gentle traction
without complication 10 months after device implantation.
A ventricular lead was not reimplanted in an alternatepen access article under the CC BY-NC-ND license
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KEY TEACHING POINTS
 Endocardial leads from cardiac devices have the
potential to interfere with tricuspid valve function.
This process should be considered in patients who
present with signs or symptoms compatible with
tricuspid valve dysfunction after device
implantation.
 Surgical management of endocardial lead–related
tricuspid regurgitation (ELTR) is generally favored
in the literature; however, there are limited data to
guide treatment.
 Our case suggests that percutaneous lead removal
may have a role even in advanced cases of ELTR and
that subsequent recovery of right ventricular
function can be delayed.
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remained in persistent AF.
When seen in clinic 3 months afterwards, she continued
to have marked right heart failure. A repeat TTE showed
persistent severe TR with severe RV dysfunction and moderateFigure Echocardiographic images. A: Apical 4-chamber view demonstrating po
ventricular (RV) dilatation 6 months after pacemaker implantation. B: Doppler sign
determined. C: Three-dimensional echocardiogram showing the pacemaker lead (w
septal (red) TV leaﬂets. Restriction of septal leaﬂet systolic excursion was observed
4-chamber view demonstrating improved TV leaﬂet coaptation and normalization o
(not shown).RV dilatation but normalized LVEF. At 5 months post–lead
extraction, she was readmitted to hospital for diuresis and
paracentesis, and to explore the option of TV surgery. However,
given her frailty, advanced age, and high procedural risk of
surgical options, it was decided to continue conservative
management. After a prolonged stay in hospital, Palliative Care
was consulted and she was discharged home with a guarded
prognosis, brieﬂy requiring a stay in a palliative care hospital
unit for delirium attributed to aggressive diuresis. A repeat TTE
the following month was unchanged.
However, over the subsequent few months her sympto-
matic status progressively improved and a TTE performed
12 months post–lead extraction revealed only mild TR
with normal biventricular size and function. She was once
again living in her retirement home, was walking on a
daily basis, and had not required any further hospital
admissions.Discussion
Clinically signiﬁcant ELTR is thought to be relatively rare,
but its incidence, prevalence, and clinical impact are
unknown and likely underappreciated.1,3 In addition to the
potential morbidity associated with the condition, it likelyor coaptation of tricuspid valve (TV) leaﬂets, biatrial enlargement, and right
al conﬁrmed severe tricuspid regurgitation (TR), but its etiology could not be
hite arrowhead) lying in the commissure between the posterior (green) and
and attributed to the lead. The anterior leaﬂet (blue) is also visible.D:Apical
f RV size 12 months after percutaneous lead extraction. Mild TR was noted
Heart Rhythm Case Reports, Vol 2, No 4, July 2016326impacts patient survival, as moderate or greater TR has been
associated with increased mortality irrespective of pulmo-
nary artery pressure and LVEF.12 However, the optimal
management of the condition remains unclear.
The strongest evidence for surgical management for
ELTR is from a case series by Lin et al2 of 41 patients
undergoing TV surgery for this indication over an 11-year
period at a single center. The authors reported 1 perioperative
death with an additional 4 deaths in follow-up, as well as
clinical improvement in all patients with follow-up data
available. However, only 19 of the cases underwent isolated
TV surgery. Furthermore, follow-up data were not available
for over one ﬁfth of surviving patients, outcomes in the
subset of isolated TV surgeries were not described sepa-
rately, and details regarding symptomatic improvement were
limited. Additional evidence in support of surgical interven-
tion for ELTR stems from case reports and small case series,
mostly of patients who underwent lead removal and TV
repair or replacement. Nearly all of these cases describe some
degree of symptomatic or echocardiographic improvement,
with no deaths reported either in the perioperative period or
at follow-up (Supplementary Table 2, available online).
Evidence for percutaneous interventions for ELTR sim-
ilarly consists of observational data. Nazmul et al9 retro-
spectively reviewed all cardiac device procedures performed
at a single center over an 11-year period and identiﬁed only 4
patients who underwent percutaneous RV lead extraction for
ELTR with ventricular lead reimplantation in the coronary
sinus. One patient died 8 days post–lead extraction and only
1 patient was noted to have modest echocardiographic
improvement in TR severity following the procedure, despite
all extractions occurring within 1 year of lead implantation. It
was proposed that tricuspid annular dilatation, which was
present in all cases, may be both a marker and a mechanism
for irreversible ELTR and therefore that surgical options may
be required once it occurs. In contrast, Polewczyk et al10
described improvement in TV function in 15 of 24 patients
with lead-related TV dysfunction (20 with severe ELTR, 4
with coexisting tricuspid stenosis) treated with percutaneous
lead extraction despite reimplantation of an RV lead in the
majority of cases. “Marked clinical improvement” was noted
in 75% of patients at a mean follow-up of 1.5 years,
including improved exercise tolerance and peripheral edema.
However, many cases of ELTR in their series were attributed
to atrial or LV leads, which have not been described by
others as causes of the condition, and details regarding
RV function, time course of recovery, or frequency of
TV damage during lead extraction were not provided.
Wardell et al11 recently described 6 patients with presumed
ELTR who underwent percutaneous RV lead removal and
reimplantation. Four had prompt clinical improvement;
however, 1 patient did not, and died soon afterward, while
another required surgical repair for iatrogenic TV damage
(Supplementary Table 2).
Wardell et al11 proposed that ventricular septal ﬂattening
on echocardiography in the absence of an alternate explan-
ation for RV dysfunction may be of diagnostic value forELTR and that it may predict whether percutaneous RV lead
reimplantation could be beneﬁcial. Though LV septal ﬂat-
tening during end-diastole on echocardiography (resulting in
a “D-shaped” cavity or an elevated “eccentricity index”) is
suggestive of RV volume overload,13 in cases of suspected
ELTR cautious interpretation of this ﬁnding is required, as it
may not distinguish between lead-related and lead-unrelated
etiologies or elucidate the mechanism of ELTR, and there-
fore it may not be sufﬁcient to determine the safety of either
percutaneous or surgical RV lead removal (or reimplanta-
tion)—determinations that are needed to predict either
intervention’s net beneﬁt. Indeed, the limitations of 2-
dimensional echocardiography and the unique and emerging
potential for 3DE in diagnosing and characterizing ELTR are
illustrated in our case and have previously been reported by
others.1,6,14 Three-dimensional echocardiography is able to
simultaneously visualize all TV leaﬂets, their coaptation, and
the precise course of the lead, which more clearly establishes
the etiology and mechanism of TR.1 Mediratta et al14
reported that leads in commissural positions as identiﬁed
by 3DE (as in our patient’s case) were associated with less
severe TR; however, their study included relatively few
subjects with severe TR, the measure of TR severity used
(vena contracta width) has not been deﬁned for nonsevere
TR, and details regarding patient symptoms or the indica-
tions for 3DE studies were not provided.
The ﬁndings in our case are consistent with severe TR due
to entrapment of a TV leaﬂet rather than direct structural
damage to the TV. However, indirectly structural changes to
the TV apparatus occurred, as the hemodynamic consequen-
ces of the regurgitant volume likely resulted in right atrial
and RV enlargement with accompanying tricuspid annular
dilatation. Once this process reaches a critical stage, RV
lead removal alone may not sufﬁce, as signiﬁcant TR may
persist. Indeed, this mechanism has been put forth by others
to explain a lack of echocardiographic or symptomatic
improvement following percutaneous lead removal alone in
certain cases.9 The risk of developing adhesions between the
lead and TV apparatus may further support early interven-
tion, particularly if a percutaneous strategy is being consid-
ered, because once such changes occur, surgery may be the
only option. However, though the beneﬁts of surgically
addressing functional TR and/or tricuspid annular dilatation
at the time of mitral valve surgery is increasingly recognized,
the role of surgery for isolated TR is not well established and
the procedure is rarely performed.3 Furthermore, though
signiﬁcant TR is often described as a progressive condition,
data comparing surgical and nonsurgical management of TR
are scarce,3 and the natural history of residual TR after RV
lead removal for ELTR, in particular, has not been studied.
Furthermore, contrary to the body of literature on LV
reverse remodeling, there is comparatively little data on the
time course of this process in the RV. Studies of surgical TV
correction for TR have reported improved RV function
within 6 months.4 In our case, signiﬁcant echocardiographic
and symptomatic improvements occurred despite severe
symptoms, RV dysfunction, and tricuspid annular dilatation,
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of improvement and delay have not been reported with
percutaneous lead extraction alone and highlight the poorly
understood pathophysiology and poorly deﬁned optimal
treatment of ELTR and of TR and RV dysfunction in
general.
Of note, reduced RV ﬁlling pressures from aggressive
diuresis likely contributed to our patient’s improved TR.
Additionally, AF has been hypothesized to be causally
linked to mitral regurgitation and TR and though the clinical
signiﬁcance of this purported phenomenon is debated, it is
possible that it played a role, as our patient was noted to be in
an intermittently atrial-paced rhythm during her last echo-
cardiogram.15 The degree of TR resolution and echocardio-
graphic features of the TV suggest that these were not
primary contributors, however.
Conclusion
Percutaneous lead removal represents a minimally invasive
alternative to surgery that should not be discounted as an
option for ELTR. Given the low procedural risk associated
with percutaneous options relative to surgery, it should be
particularly considered in individuals with isolated ELTR
early after device implantation, for poor surgical candidates,
and in patients with relatively preserved TV structure.
Clinicians should be aware that it may take 46 months for
RV function to recover.
Appendix
Supplementary material
Supplementary data associated with this article can be found
in the online version at http://dx.doi.org/10.1016/j.hrcr.2016.
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